Investor Presentation - First Six Months of 2021
93
Investor presentation
First six months of 2021
EMEA at a glance
Million
Diabetes trend
250
200
28%
I
150
31%
Diabetes market by value and Novo
Nordisk market share
EMEA
Novo Nordisk reported sales
DKK
billion
100
First half of 2021
Sales
(mDKK)
Growth²
80%
Total GLP-13
4,961
36%
08
80
GLP-1
Long-acting insulin
3,470
8%
60%
Premix insulin5
1,508
1%
28%1
60
40
60
40
Fast-acting insulin
3,274
1%
3%1
Human insulin
Insulin
1,110
(9%)
40%
Total insulin
9,362
2%
Other Diabetes care?
353
0%
20
OAD 20%
Diabetes care
14,676
11%
20
10%1
Obesity care
839
55%
(SaxendaⓇ)
0
0%
2045
May
2016
May
2021
Diabetes & Obesity
15,515
13%
care
Biopharm³
3,594
5%
GLP-1 MS
-Insulin MS
-OAD MS
Total
19,109
11%
223
100
171
134
50
0
2019
2030
Population with diabetes
Diabetes growth rate
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019;
EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of May
2021: Novo Nordisk 48%, Sanofi 33% and Eli Lilly 16%; Competitor GLP-1 value market
shares, as of May 2021: Novo Nordisk 57%, Eli Lilly 39% and AstraZeneca 4%; OAD: Oral
anti-diabetic; MS: Market share; Source: IQVIA MAT, May 2021 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises RyzodegⓇ and
NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily NovoSeven®, Novo Eight® NovoThirteenⓇ,
Refixia®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation